The results demonstrated that Fbxo22 deficiency had no effect on GFP+ leukemia cells in PB of primary recipient mice at 5 weeks after transplantation, but slightly inhibited GFP+ myeloid leukemia cells in BM of these recipient mice (Additional file 4: Fig. S3C, D). This evidence concerns the gene FBXO22 and myeloid leukemia.